Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -88.24% is 23% below its 5-year average of -71.92%, around the middle of its 5-year range (-173.17%–-8.51%).
36.67% above its 12-month average of -139.34%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -22.59%.
RETURN ON ASSETS (ROA)
-88.24%
RETURN ON ASSETS (ROA) AVG TTM
-139.34%
RETURN ON ASSETS (ROA) AVG 3Y
-100.15%
RETURN ON ASSETS (ROA) AVG 5Y
-71.92%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+36.67%
CURRENT VS 3Y AVG
+11.89%
CURRENT VS 5Y AVG
-22.70%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-24.95%
median of 444 covered companies
CURRENT VS SECTOR MEDIAN
-253.67%
vs the sector median at left
Biomea Fusion, Inc.
Market Cap
$93.99M
Return on Assets (ROA)
-88.24%
TTM Avg
-139.34%
3Y Avg
-100.15%
5Y Avg
-71.92%
Market Cap
$91.68M
Return on Assets (ROA)
-30.70%
TTM Avg
-50.88%
3Y Avg
-51.94%
5Y Avg
-48.05%
Market Cap
$91.33M
Return on Assets (ROA)
-86.56%
TTM Avg
-66.44%
3Y Avg
-84.84%
5Y Avg
-75.69%
Market Cap
$88.21M
Return on Assets (ROA)
1.69%
TTM Avg
-3.62%
3Y Avg
-6.49%
5Y Avg
-4.78%
Market Cap
$87.86M
Return on Assets (ROA)
-107.29%
TTM Avg
-60.42%
3Y Avg
-51.23%
5Y Avg
-39.69%
Market Cap
$100.37M
Return on Assets (ROA)
-69.14%
TTM Avg
-63.05%
3Y Avg
-52.31%
5Y Avg
-58.69%
Market Cap
$86.69M
Return on Assets (ROA)
8.52%
TTM Avg
11.64%
3Y Avg
-8.81%
5Y Avg
-6.61%
Market Cap
$84.75M
Return on Assets (ROA)
-74.91%
TTM Avg
-50.52%
3Y Avg
-40.48%
5Y Avg
-70.00%
Market Cap
$84.70M
Return on Assets (ROA)
-79.38%
TTM Avg
41.63%
3Y Avg
-36.06%
5Y Avg
-44.84%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | $93.99M | -88.24% | -139.34% | -100.15% | -71.92% |
| Equillium, Inc. (EQ)vs › | $91.68M | -30.70% | -50.88% | -51.94% | -48.05% |
| electroCore, Inc. (ECOR)vs › | $91.33M | -86.56% | -66.44% | -84.84% | -75.69% |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 1.69% | -3.62% | -6.49% | -4.78% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | -107.29% | -60.42% | -51.23% | -39.69% |
| Anixa Biosciences, Inc. (ANIX)vs › | $100.37M | -69.14% | -63.05% | -52.31% | -58.69% |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 8.52% | 11.64% | -8.81% | -6.61% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | -74.91% | -50.52% | -40.48% | -70.00% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | -79.38% | 41.63% | -36.06% | -44.84% |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -70.05% | -71.47% | -58.80% | -51.13% |
ROA
-88.2%
ROE
-268.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -105.51% |
| 2024-12-31 | -173.17% |
| 2023-12-31 | -58.65% |
| 2022-12-31 | -63.28% |
| 2021-12-31 | -22.38% |
| 2020-12-31 | -8.51% |
| 2019-12-31 | -452.08% |
